title: Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: giulia.fontanelli@yahoo.it.
authors.forename: Giulia
authors.initials: G
authors.lastname: Fontanelli
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Melania
authors.initials: M
authors.lastname: Rocco
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Caracciolo
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Edoardo
authors.initials: E
authors.lastname: Benedetti
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Buda
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Orciuolo
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Carulli
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Galimberti
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Azzarà
authors.affiliation: U.O. Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Petrini
mesh_terms: D000227:Adenine Nucleotides / Q000008:administration & dosage*; D000328:Adult; D001087:Arabinonucleosides / Q000008:administration & dosage*; D000077866:Clofarabine; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D000077157:Sorafenib; D020080:Tandem Repeat Sequences / Q000235:genetics*; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D010671:Phenylurea Compounds; D003561:Cytarabine; D009536:Niacinamide; D000077866:Clofarabine; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3
keywords: Acute myeloid leukemia; Clofarabine; FLT3 inhibitors; FLT3 mutation; Sorafenib